GeoVax Aligns Vaccine Pipeline with U.S. Global Health Strategy, Emphasizing Pandemic Preparedness

GeoVax Labs, Inc. announced its strong support for the newly unveiled America First Global Health Strategy by U.S. Secretary of State Marco Rubio, emphasizing how the company's vaccine pipeline aligns with strategic initiatives to strengthen American health security. The clinical-stage biotechnology company develops multi-antigen vaccines and immunotherapies against infectious diseases and cancers, with programs that directly support the policy's pillars of making America safer, stronger, and more prosperous through domestic innovation and manufacturing capabilities.

The strategy highlights the urgent need for rapid outbreak detection and deployment of medical countermeasures, areas where GeoVax is making significant advancements. The company is developing a continuous cell-line manufacturing technology that will enhance scalability, speed, and resilience in vaccine production, addressing longstanding supply chain vulnerabilities in U.S. biodefense. This advanced manufacturing process supports GeoVax's MVA-based platform, which is designed for rapid vaccine response against multiple infectious disease threats including Mpox, smallpox, Zika, and hemorrhagic fever viruses.

GeoVax's commitment to developing regional supply capabilities aims to ensure timely and equitable access to vaccines worldwide. The company's GEO-MVA program for Mpox and smallpox recently received favorable scientific advice from the European Medicines Agency recommending an expedited regulatory pathway through an immuno-bridging study. This regulatory guidance provides a potentially faster path to approval while accelerating GeoVax's commercialization and revenue opportunities, reinforcing the company's position as a U.S.-based innovator in global health security. For more information about the company's clinical trials and updates, visit https://www.geovax.com.

The America First strategy emphasizes leveraging U.S. foreign assistance procurements to expand global access to American-made health solutions. GeoVax positions itself as a domestic alternative to existing foreign monopolies in poxvirus vaccines, supporting national security priorities while strengthening U.S. competitiveness in emerging global health markets. This alignment with government strategy represents a significant opportunity for American biotechnology companies to contribute to global health while advancing domestic economic interests.

With the strategy calling for bilateral health agreements and integration with local health systems, GeoVax's multi-antigen vaccine design offers other countries efficient, cost-effective solutions that reduce dependency on fragmented healthcare programs. The company's approach directly complements U.S. goals of building resilient, country-led health systems through technological innovation and strategic partnerships.

David Dodd, Chairman and CEO of GeoVax, stated that the America First Global Health Strategy represents a historic opportunity to align U.S. innovation with global health needs while strengthening American leadership and protecting citizens and the economy. The company's vaccine and immunotherapy programs are designed to deliver innovation, security, and scalability in line with strategic national priorities for health security and economic prosperity.